<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394055</url>
  </required_header>
  <id_info>
    <org_study_id>RM-131-003</org_study_id>
    <nct_id>NCT01394055</nct_id>
  </id_info>
  <brief_title>Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis</brief_title>
  <official_title>Official Title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose, 2-Period Crossover Study to Evaluate the Pharmacodynamics of RM-131 Administered to Patients With Diabetic Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Motus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Motus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK)
      profile and the safety and tolerability of RM-131 in patients with diabetes mellitus and
      delayed gastric emptying.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic (PD) effects of RM-131 on gastric emptying</measure>
    <time_frame>Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 1 and Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 2</time_frame>
    <description>Change from baseline in gastric half-emptying time by scintigraphy (solids and liquids)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of RM-131</measure>
    <time_frame>Day 1 and 2 after dosing in Period 1 and Day 1 and 2 after dosing in Period 2</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of RM-131</measure>
    <time_frame>Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 1 and Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 2</time_frame>
    <description>Median T-max of RM-131 levels in patients with type 2 diabetes mellitus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus Type 1 and 2</condition>
  <condition>Diabetes Mellitus Complications</condition>
  <condition>Gastroparesis</condition>
  <condition>Gastrointestinal Motility Disorder</condition>
  <arm_group>
    <arm_group_label>RM-131</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RM-131</intervention_name>
    <description>100 μg subcutaneously once</description>
    <arm_group_label>RM-131</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo volume subcutaneously once</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Able to provide written informed consent prior to any study procedures.

          -  Diagnosis of Type 1 or 2 diabetic gastroparesis.

          -  Controlled Type 1 or 2 diabetes mellitus (HbA1c &lt;10.1%).

          -  Stable concomitant medications defined as no changes in regimen for at least 2 weeks
             prior to Period 1 (daily adjustments of insulin doses are permitted).

          -  Body mass index of 18-40 kg/m².

        Key Exclusion Criteria:

          -  Unable or unwilling to provide informed consent or to comply with study procedures.

          -  History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker
             placement, vagotomy, bariatric procedure. (Note: history of diagnostic endoscopy is
             not exclusionary).

          -  Acute or chronic illness or history of illness, which in the opinion of the
             Investigator, could pose a threat or harm to the patient or obscure interpretation of
             laboratory test results or interpretation of study data such as frequent angina, Class
             III or IV congestive heart failure, poor renal or hepatic function, etc.

          -  Any clinically significant abnormalities on screening laboratories as determined by
             the Investigator.

          -  Abnormal 12-lead electrocardiogram (ECG), including evidence of acute myocardial or
             subendocardial ischemia and clinically significant arrhythmias or conduction
             abnormalities or blood pressure at screening except minor deviations deemed to be of
             no clinical significance by the Investigator.

          -  Poor venous access or inability to tolerate venipuncture.

          -  Acute GI illness within 48 hours of Period 1.

          -  Positive pregnancy test.

          -  Participation in a clinical study within the 30 days prior to dosing in the present
             study.

          -  Any other reason, which in the opinion of the Investigator, would confound proper
             interpretation of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2011</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus Type 1 and 2</keyword>
  <keyword>Delayed Gastric Emptying</keyword>
  <keyword>Gastroparesis</keyword>
  <keyword>Gastrointestinal Motility Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Gastroparesis</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

